Use of rodents as models of human diseases

Journal of Pharmacy and Bioallied Sciences

Volumn 6, Issue 1, 2014, Pages 2-9

  Vandamme, Thierry ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Cancer; genetically modified animals; human diseases; rodents; transgenic

Indexed keywords

ARACHIDONIC ACID; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; CANCER RESEARCH; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE MODEL; DNA MODIFICATION; DRUG DEVELOPMENT; DRUG RESEARCH; ENDOMETRIUM CARCINOMA; ENTERITIS; EXPERIMENTAL MOUSE; FATTY LIVER; IMAGING SYSTEM; INSULIN RESISTANCE; NONHUMAN; OVARY ADENOCARCINOMA; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RODENT MODEL; TOBACCO DEPENDENCE; TRANSGENIC MOUSE;

EID: 84899726499     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.124301     Document Type: Review

References (58)

1. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
2. Angstadt AY, Thayanithy V, Subramanian S, Modiano JF, Breen M. A genome-wide approach to comparative oncology: High-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations. Cancer Genet 2012;205:572-87.
3. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004;40:858-80.
4. Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 2010;10:375-9.
5. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-50.
6. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, et al. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59:749-52.
7. McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2012;26:910-7.
8. Yun SH, Park ES, Shin SW, Na YW, Han JY, Jeong JS, et al. Stichoposide C induces apoptosis through the generation of ceramide in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 2012;18:5934-48.
9. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337:644-54.
10. Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X, et al. The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo. J Cancer Res Clin Oncol 2012;138:1321-8.
11. Chughtai K, Jiang L, Greenwood TR, Glunde K, Heeren RM. Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor models. J Lipid Res 2013;54:333-44.
12. Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, et al. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Res 2012;14:R132.
13. Chang JT, Kuo TF, Chen YJ, Chiu CC, Lu YC, Li HF, et al. Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther 2010;17:827-36.
14. Chen Y, Ma J, Wang F, Hu J, Cui A, Wei C, et al. Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells. Immunopharmacol Immunotoxicol 2013;35:43-51.
15. Tu Z, Ma Y, Tian J, Li H, Akers W, Achilefu S, et al. Estrogen receptor potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells. J Cancer Res Clin Oncol 2012;138:1091-103.
16. Lin J, Yu Y, Shigdar S, Fang DZ, Du JR, Wei MQ, et al. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. PLoS One 2012;7:e49277.
17. Yin P, Wang Y, Qiu Y, Hou L, Liu X, Qin J, et al. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: Preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomedicine 2012;7:3961-9.
18. Zhang H, Zhang S, He H, Zhao W, Chen J, Shao RG. GAP161 targets and downregulates G3BP to suppress cell growth and potentiate cisplaitin-mediated cytotoxicity to colon carcinoma HCT116 cells. Cancer Sci 2012;103:1848-56.
19. Hsu CW, Chang YJ, Chang CH, Chen LC, Lan KL, Ting G, et al. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. Cancer Biother Radiopharm 2012;27:481-9.
20. Burden RE, Gormley JA, Kuehn D, Ward C, Kwok HF, Gazdoiu M, et al. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie 2012;94:487-93.
21. James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, et al. CEP-32496: A novel orally active BRAF (V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther 2012;11:930-41.
22. Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, et al. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med 2012;53:1592-600.
23. Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 2006;119:783-91.
24. Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, et al. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther 2012;11:383-92.
25. Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 2013;21:358-67.
26. Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, et al. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res 2013;73:716-24.
27. Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, et al. Stromal platelet-derived growth factor receptor (PDGFR) provides a therapeutic target independent of tumor cell PDGFRexpression in lung cancer xenografts. Mol Cancer Ther 2012;11:2473-82.
28. Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS One 2012;7:e42345.
29. Wang H, Galbán S, Wu R, Bowman BM, Witte A, Vetter K, et al. Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res 2013;19:158-69.
30. Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, et al. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res 2011;17:6531-41.
31. Choi ES, Jung JY, Lee JS, Park JH, Cho NP, Cho SD. Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Lett 2013;328:65-72.
32. Authier S, Tremblay S, Dumulon V, Dubuc C, Ouellet R, Lecomte R, et al. [11C] acetoacetate utilization by breast and prostate tumors: A PET and biodistribution study in mice. Mol Imaging Biol 2008;10:217-23.
33. Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, et al. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol 2012;41:1199-203.
34. Kamran MZ, Gude RP. Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. Biomed Pharmacother 2012;66:617-26.
35. Yu K, Chen Z, Pan X, Yang Y, Tian S, Zhang J, et al. Tetramethylpyrazine- mediated suppression of C6 gliomas involves inhibition of chemokine receptor CXCR4 expression. Oncol Rep 2012;28:955-60.
36. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol 2009;1:32.
37. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J 2012;279:1156-66.
38. Forabosco F, Löhmus M, Rydhmer L, Sundström LF. Genetically modified farm animals and fish in agriculture: A review. Livestock Sci 2013;153:1-9.
39. Sharpless NE, Depinho RA. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
40. Jones TS, Holland EC. Animal models for glioma drug discovery. Expert Opin Drug Discov 2011;6:1271-83.
41. Flisikowska T, Kind A, Schnieke A. The new pig on the block: Modelling cancer in pigs. Transgenic Res 2013;22:673-80.
42. European Commission. Of mice and men - Are mice relevant models for human disease? Outcomes of the European Commission workshop "Are mice relevant models for human disease?" held in London, UK, on May 2010.
43. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 2006; 66: 3355-8, 3358.
44. Schuh JC. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 2004;32 Suppl 1:53-66.
45. Gong C, Deng S, Wu Q, Xiang M, Wei X, Li L, et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 2013;34:1413-32.
46. Dong LF, Grant G, Massa H, Zobalova R, Akporiaye E, Neuzil J. -Tocopheryloxyacetic acid is superior to -tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability. Int J Cancer 2012;131:1052-8.
47. Mueller M, Reichardt W, Koerner J, Groettrup M. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J Control Release 2012;162:159-66.
48. Zhong ZF, Hoi PM, Wu GS, Xu ZT, Tan W, Chen XP, et al. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo. J Ethnopharmacol 2012;141:721-7.
49. van den Engel NK, Rüttinger D, Rusan M, Kammerer R, Zimmermann W, Hatz RA, et al. Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer. J Transl Med 2011;9:140.
50. Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011;129:225-32.
51. Bergé M, Bonnin P, Sulpice E, Vilar J, Allanic D, Silvestre JS, et al. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 2010;177:3192-201.
52. Rennick DM, Fort MM. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2000;278:G829-33.
53. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest 2008;118:829-38.
54. Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: Lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009;89:991-1023.
55. Changeux JP. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat Rev Neurosci 2010;11:389-401.
56. Bosetti F. Arachidonic acid metabolism in brain physiology and pathology: Lessons from genetically altered mouse models. J Neurochem 2007;102:577-86.
57. Wang X, Deng Y, Mao Z, Ma X, Fan X, Cui L, et al. CCN1 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway in pancreatic cancer. Tumour Biol 2012;33:1745-58.
58. Mohammed A, Janakiram NB, Lightfoot S, Gali H, Vibhudutta A, Rao CV. Early detection and prevention of pancreatic cancer: Use of genetically engineered mouse models and advanced imaging technologies. Curr Med Chem 2012;19:3701-13.